预后营养指数（PNI）已成为评估患者营养状况和免疫能力的重要预测工具。它广泛用于各种癌症患者的预后评估。然而，预后营养指数（PNI）对于接受免疫检查点抑制剂（ICIs）治疗的胃癌或胃食管交界癌患者（GC/GEJC）的预后相关性仍不清楚。这项荟萃分析旨在确定 PNI 对这一特定患者队列的预后影响。我们进行了彻底的文献检索，涵盖 PubMed、Embase、Web of Science、SpringerLink 和 Cochrane 图书馆等著名数据库。检索时间从这些数据库建立之初一直持续到2023年12月5日。该研究采用95%置信区间和风险比（HR），系统评估了PNI与关键预后指标（包括客观缓解率（ORR））之间的关系接受 ICI 治疗的 GC/GEJC 患者的疾病控制率 (DCR)、总生存期 (OS) 和无进展生存期 (PFS)。选择了包含 813 名符合条件的患者的八项研究。 7 项研究一致证明，高预后营养指数 (PNI) 组的总生存期 (OS) 优于低 PNI 组（HR 0.58，95% CI：0.47-0.71，P<0.001）。此外，6项研究的结果指出，低PNI与较差的无进展生存期（PFS）之间存在显着相关性（HR 0.58，95% CI：0.47-0.71，P<0.001）。进行亚组分析以验证结果的稳健性。此外，我们对三项研究进行了荟萃分析，考察了 PNI 与客观缓解率/疾病控制率 (ORR/DCR) 之间的相关性，发现 ORR/DCR 在高 PNI 组中显着优于 (ORR: RR: 1.24，P=0.002；DCR：RR：1.43，P=0.008）。该荟萃分析表明，接受 ICI 治疗的 GC/GEJC 患者的低 PNI 与较差的 OS 和 PFS 显着相关。因此，PNI 可以作为接受 ICI 的 GC 患者治疗后结果的预后指标。需要进一步的前瞻性研究来评估这些发现的可靠性。https://inplasy.com/，标识符 IPLASY202450133。版权所有 © 2024 Hou、Song、Hao、Li、Zhang 和 Zhu。

The Prognostic Nutritional Index (PNI) has become an important predictive tool for assessing patients' nutritional status and immune competence. It is widely used in prognostic evaluations for various cancer patients. However, the prognostic relevance of the Prognostic Nutritional Index (PNI) in gastric or gastro-esophageal junction cancer patients (GC/GEJC) undergoing immune checkpoint inhibitors (ICIs) treatment remains unclear. This meta-analysis aimed to determine the prognostic impact of PNI in this specific patient cohort.We conducted a thorough literature search, covering prominent databases such as PubMed, Embase, Web of Science, SpringerLink, and the Cochrane Library. The search spanned from the inception of these databases up to December 5, 2023. Employing the 95% confidence interval and Hazard Ratio (HR), the study systematically evaluated the relationship between PNI and key prognostic indicators, including the objective remission rate (ORR), disease control rate (DCR), overall survival (OS) and progression-free survival (PFS) in GC/GEJC patients undergoing ICI treatment.Eight studies comprising 813 eligible patients were selected. With 7 studies consistently demonstrating superior Overall Survival (OS) in the high-Prognostic Nutritional Index (PNI) group compared to their low-PNI counterparts (HR 0.58, 95% CI: 0.47-0.71, P<0.001). Furthermore, the results derived from 6 studies pointed out that the significant correlation between he low-PNI and poorer progression-free survival (PFS) (HR 0.58, 95% CI: 0.47-0.71, P<0.001). Subgroup analyses were performed to validate the robustness of the results. In addition, we conducted a meta-analysis of three studies examining the correlation between PNI and objective response rate/disease control rate (ORR/DCR) and found that the ORR/DCR was significantly superior in the high PNI group (ORR: RR: 1.24, P=0.002; DCR: RR: 1.43, P=0.008).This meta-analysis indicates that the low-PNI in GC/GEJC patients undergoing ICI treatment is significantly linked to worse OS and PFS. Therefore, PNI can serve as a prognostic indicator of post-treatment outcomes in patients with GC receiving ICIs. Further prospective studies are required to assess the reliability of these findings.https://inplasy.com/, identifier INPLASY202450133.Copyright © 2024 Hou, Song, Hao, Li, Zhang and Zhu.